NICE technology appraisal guidance
Issued: April 2009
TA170
Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta170
8 Review of guidance
8.1 The review date for a technology appraisal refers to the month and year in which the Guidance Executive will consider whether the technology should be reviewed. This decision will be taken in the light of information gathered by the Institute, and in consultation with consultees and commentators.
8.2 The guidance on this technology was considered for review in February 2012. Details are on the NICE website.
Andrew Dillon
Chief Executive
April 2009